About Michael Finney
Michael Finney is a board member at seqWell.
Michael Finney reports to the SEC as a director of 1 public company: Vaxart (VXRT).
Michael Finney first appears on SEC filings in 2017.
Experience
This experience comes from Michael Finney's profile and from SEC filings. For roles taken from filings, the years are when the filings name Michael Finney in the role, so the role may have started earlier or lasted longer.
KA
KaRNATeq Current
Board Chair
2019 – Present
seqWell Inc. Current
Board Member
2016 – Present · Beverly, MA
DNA sequencing preparation kits for research laboratories.
TI
Thrive Bioscience, Inc. Current
Board Chair
2014 – Present
LA
Life Science Angels Current
Member
2006 – Present
SS
Sage Science Current
Board Chair
2005 – Present
FC
Finney Capital Current
Managing Director
2004 – Present
TA
The Genome Partnership — AGBT Current
Director and Permanent Member
1999 – Present
OG
Orion Genomics Current
Director
1998 – Present
VI
Vaxart, Inc.
Board Chair (2007 – 2025)
Interim Chief Executive Officer (2024)
2007 – 2025 · Public company (VXRT)
SG
S2 Genomics
Director
2019 – 2025
MB
Massachusetts General Hospital Department of Molecular Biology
Mars Team
1996 – 2024
AT
Addition Therapeutics
Board Chair and Co-Founder
2021 – 2023
CB
Chimera Bioengineering
Director
2017 – 2019
NI
Nanotech Biomachines, Inc.
Director
2016 – 2018
BE
Banyan Energy
Director
2013 – 2016
IR
Innerscope Research
Director
2009 – 2015
WA
WaveMark
Director
2004 – 2013
MM
Mission Motors
Director
2009 – 2010
PH
Pharmasecure
Director
2009
MI
MJ Research, Inc.
CSO and Board Director
1985 – 2004
Key Colleagues at Startups
The people Michael Finney works with at each company, as listed on that company's latest Form D.
seqWell Inc. · Form D, Sep 10, 2026
DC
Daniel Calvo
Chief Executive Officer and director
AL
Amy Liao
Board Member
AP
Anup Parikh
Board Member
TG
Thomas Grant
Chief Financial Officer
PM
Paul McEwan
Chairman of the Board
JM
Joseph Mellor
Chief Scientific Officer and Co-Founder, director
CS
Chad Souvignier
Board Member